Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.45
<$0.01(0.16%)
At close: 4:00 PM EST
$14.45
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$5.68 - $18.38
Previous CloseN/A
Volume25.45K
Average Volume (3M)813.77K
Market Cap
$410.08M
Enterprise Value$85.38M
Total Cash (Recent Filing)$118.75M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 18, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding26,525,160
10 Day Avg. Volume1,111,483
30 Day Avg. Volume813,766
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$37.40Price Target Upside158.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 LEVEL TrialA near-term registrational readout with a late-breaking ESC slot is a durable, program-defining catalyst. Positive topline data would materially de-risk regulatory path, create first-in-class positioning in PH-HFpEF, enable commercialization or partnerships, and change strategic options over the next several months.
Supply & Licensing StabilityA long-term manufacturing partner and extended license timeline materially reduce execution risk for commercialization. Secured supply, defined scale-up terms and an extended approval deadline provide operational certainty, lower production bottleneck risk, and improve negotiation leverage with partners and payers.
Conservative Balance SheetA debt-free capital structure and recent sizable equity raises reduce solvency and interest-rate risk during the development phase. This financial flexibility supports running pivotal programs and pursuing strategic options without immediate debt servicing constraints, giving management runway to advance the program over coming months.
Bears Say
Widening LossesMaterial and growing operating losses without product revenue mean the company must rely on external capital to complete development. Over the next 2–6 months this elevates dilution and execution risk, may force prioritization of activities, and constrains the ability to pursue broader commercial readiness simultaneously.
Escalating Cash BurnA worsening operating cash flow trend signals rising funding needs as trials scale. Continued negative cash generation compresses runway, forces near-term financing or partnership decisions, and increases the probability of dilutive raises or trade-offs that could delay other development or commercialization activities.
Funding DependenceWith no meaningful recurring revenues before approval, the company is structurally dependent on external financing or partnerships. This creates persistent execution risk: if markets shift or deal timelines slip in the next months, Tenax may face constrained strategic flexibility, higher dilution, or delayed programs.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $5.68 and its highest was $18.38 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $410.08M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 42 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on May 12, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.047.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 26,525,160 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went up 1.841%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.40 (158.82% Upside)
$37.40 (158.82% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.33%
12-Months-Change
Fundamentals
Return on Equity
-56.32%
Trailing 12-Months
Asset Growth
9.92%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$37.40
▲(158.82% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.16% Insiders
12.05% Mutual Funds
42.80% Other Institutional Investors
39.25% Public Companies and
Individual Investors